Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study

Transplantation

Volumn 79, Issue 4, 2005, Pages 466-475

  Dudley, Christopher ^a   Pohanka, Erich ^b   Riad, Hany ^c   Dedochova, Jarmila ^d   Wijngaard, Peter ^e   Sutter, Carolyn ^e   Silva Jr , Hélio Tedesco ^f  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d Internal Clinic FNsP   (Czech Republic)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic allograft nephropathy; Creeping creatinine; Cyclosporine A nephrotoxicity; Mycophenolate mofetil; Renal transplant

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANOREXIA; ARTICLE; BIOASSAY; CANDIDIASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PARAMETER; PATIENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RISK; STATISTICAL ANALYSIS; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 14044252180     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000151632.21551.00     Document Type: Article

References (26)

1. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1996; 1.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
3. Paul LC, Hayry P, Foegh M, et al. Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal for the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 1993; 25: 2022.
4. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167.
5. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
6. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706.
7. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
8. Hueso M, Bover J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727.
9. Houde I, Isenring P, Boucher D, et al. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 2000; 70: 1251.
10. Ducloux D, Fournier V, Bresson-Vautrin C, et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine associated nephrotoxicity: a preliminary report. Transplantation 1998; 65: 1504.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
12. Curtis JJ, Luke RG, Dubovsky E, et al. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477.
13. Weir MR, Klassen DK, Shen SY, et al. Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. Transplantation 1990; 49: 41.
14. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
15. Klupp J, Dambrin C, Hibi K, et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am J Transplant 2003; 3: 817.
16. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26: 3205.
17. Nadeau KC, Azuma H, Tilney NL. Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil. Transplantation 1996; 62: 1363.
18. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574.
19. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674.
20. Stegall M, Park W, Kim D, et al. Gene expression during acute allograft rejection: novel statistical analysis of microarray data. Am J Transplant 2002; 2: 913.
21. Schrama YC, Joles JA, van Tol A, et al. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69: 376.
22. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119.
23. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001; 23: 717.
24. Mathew TH. A blinded, long-term, randomised multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
25. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391.
26. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.